Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

STERIS plc (STE) — XLV Health Care · S&P 500 Profile |STERIS公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

STERIS plc (STE) — Business, History & S&P 500 Profile |STERIS公司介紹

STERIS company profile · infection prevention & procedural products: Healthcare, AST & Life Sciences · history · financial snapshot · S&P 500 rank #381 · STERIS公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 3, 2026
Financials: Fiscal 2026 (ended Mar 31, 2026)
MARKET CAP
$22.56B
Nov 3, 2026 · StockAnalysis
S&P 500 WEIGHT
0.03%
Rank #381 · Nov 3, 2026 (Slickcharts)
FISCAL 2026 REVENUES
$5.94B
+8.7% YoY · year ended Mar 31, 2026
FISCAL 2026 NET INCOME ATTRIBUTABLE
$782.3M
Diluted EPS from continuing operations $7.93

SNAPSHOT

TickerSTE (NYSE)
CompanySTERIS plc
GICS sector / industryHealth Care / Health Care Equipment
S&P 500 rank (by weight)#381 · 0.03% (Nov 3, 2026)
Sector rank (by S&P 500 weight)#47 in Health Care (Nov 3, 2026)
HeadquartersMentor, Ohio (operational HQ; incorporated in Ireland)
Founded1985
CEODaniel A. Carestio
Market cap$22.56B (Nov 3, 2026)
SEC filingsEDGAR — CIK 0001757898

WHAT IT DOES

STERIS is a global provider of products and services that support patient care with an emphasis on infection prevention: consumables such as detergents and barrier products, services including equipment maintenance, instrument repair and outsourced reprocessing, capital equipment such as sterilizers and surgical tables, and operating-room connectivity. It reports three segments — Healthcare, Applied Sterilization Technologies (AST) and Life Sciences — after divesting its Dental segment in fiscal 2025, which is now shown as discontinued operations.

Revenues from continuing operations were $5,935.9M in fiscal 2026, up 8.7% on fiscal 2025, with constant-currency organic growth of 7.3%. Healthcare, at $4,208.6M, supplied 70.9% of revenues and grew 8.5% on service (+11.8%), consumable (+7.2%) and capital (+5.7%) growth; AST grew 9.6% to $1,138.5M on pricing and volume despite a sharp fall in capital-equipment sales, and Life Sciences grew 8.6% to $588.8M.

Segment operating income before adjustments was $1,381.9M, but reported income from operations was $1,101.8M after $265.0M of acquired-intangible amortisation and other adjustments. Net income attributable to shareholders was $782.3M, with diluted EPS from continuing operations of $7.93. Healthcare’s segment margin slipped to 24.6% from 25.0% as tariffs and inflation more than offset volume, pricing and productivity gains.

REVENUES BY SEGMENT — FISCAL 2026

SegmentRevenuesShareYoY
Healthcare$4,208.6M70.9%+8.5%
Applied Sterilization Technologies (AST)$1,138.5M19.2%+9.6%
Life Sciences$588.8M9.9%+8.6%
Total revenues$5,935.9M100%+8.7%
Source: STERIS fiscal 2026 Form 10-K (year ended Mar 31, 2026), segment revenues and segment operating income before adjustments. Fiscal 2025 comparatives: Healthcare $3,878.7M, AST $1,038.6M, Life Sciences $542.3M, total $5,459.5M. Shares and YoY are computed from the disclosed segment revenues. Dental is presented as discontinued operations and excluded throughout.

HISTORY

YearMilestone
1985Innovative Medical Technologies founded in Mentor, Ohio, by microbiologist Raymond Kralovic
1987Renamed STERIS Corporation; Bill Sanford becomes first president and CEO
1998Moves to the New York Stock Exchange under the ticker STE
2015Acquires Synergy Health and becomes STERIS plc
2021Acquires Cantel Medical, expanding infection prevention in endoscopy and life sciences; Dan Carestio becomes president and CEO
2025Divests the Dental segment, presented thereafter as discontinued operations

COMPETITIVE POSITION

  • Installed-base service model — sterilizers and surgical tables sold once generate years of consumables, maintenance and reprocessing revenue; Healthcare service revenue grew 11.8% in fiscal 2026.
  • AST pricing power — contract sterilization for medical devices is highly regulated and concentrated; AST’s segment margin reached 46.1% in fiscal 2026.
  • Procedure demand — ageing populations and rising endoscopy and screening volumes drive steady demand for sterile processing, independent of any single drug or device cycle.
  • Competition — on products: 3M, Baxter, Getinge, Ecolab, Olympus and Stryker; on services: Sterigenics and in-house sterilization by device makers themselves.

FINANCIAL SNAPSHOT — FISCAL 2026

Revenues (continuing operations)$5,935.9M (+8.7% YoY)
Income from operations$1,101.8M (vs $866.6M in fiscal 2025)
Income from operations before adjustments$1,381.9M (vs $1,267.5M in fiscal 2025)
Net income attributable to shareholders$782.3M (vs $614.6M in fiscal 2025)
Diluted EPS from continuing operations$7.93
Free cash flow$982.9M (vs $787.2M in fiscal 2025)
Source: STERIS fiscal 2026 Form 10-K consolidated statements and segment note (year ended Mar 31, 2026). Income from operations before adjustments is a segment measure excluding corporate costs and items such as acquired-intangible amortisation ($265.0M in fiscal 2026). Fiscal 2025 figures are as restated for discontinued operations (Dental).

KEY RISKS

  • Tariffs and inflation — the 10-K attributes the Healthcare margin slip to tariff costs and inflation outrunning pricing and productivity.
  • Ethylene oxide exposure — AST sterilization uses ethylene oxide, which faces emissions regulation and litigation attention across the contract-sterilization industry.
  • Capital-equipment lumpiness — Healthcare capital revenue is seasonally weighted to the fiscal fourth quarter, and AST capital-equipment sales fell sharply in fiscal 2026.
  • Customer concentration by procedure — no single customer exceeds 10% of any segment’s revenues, but demand ultimately tracks hospital procedure volumes and capital budgets.

WHY IT MATTERS FOR THE S&P 500

STERIS is the S&P 500’s infection-prevention pure play at a 0.03% weight: the index’s exposure to hospital sterile processing and medical-device sterilization, a business that grows with procedure volumes rather than with drug prices or device launches.

Its Healthcare service growth and AST margins make it a quiet compounder inside Health Care, distinct from the drug and device makers that dominate the sector.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Nov 3, 2026 crawl) · StockAnalysis (market cap — Nov 3, 2026 crawl, single source)
FinancialsSTERIS fiscal 2026 Form 10-K (SEC EDGAR, filed May 2026; fiscal year ended Mar 31, 2026)
Sector classificationGICS via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

STERIS

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號STE(NYSE)
公司STERIS plc
GICS 板塊/行業醫療保健/Health Care Equipment
標普500排名(按權重)第381名 · 0.03%(2026 年 11 月 3 日)
板塊內排名(按標普500權重)醫療保健第47名(2026 年 11 月 3 日)
總部美國俄亥俄州門托(營運總部;於愛爾蘭註冊)
成立1985年
行政總裁Daniel A. Carestio
市值$22.56B(2026 年 11 月 3 日)
SEC 文件EDGAR — CIK 0001757898

業務概覽

STERIS 是一家全球供應商,提供支援病人護理的產品與服務,重點在於感染預防:消耗品如清潔劑及屏障產品、服務包括設備維護、器械維修及外判再處理、資本設備如滅菌器及手術台,以及手術室連接方案。公司報告三個分部——醫療保健、應用滅菌技術(AST)及生命科學——於 2025 財政年度出售牙科分部後,該分部現列為已終止經營業務。

2026 財政年度持續經營業務收入為 $5,935.9M,較 2025 財政年度增長 8.7%,按固定匯率有機增長 7.3%。醫療保健分部收入 $4,208.6M,佔收入 70.9%,增長 8.5%,服務(+11.8%)、消耗品(+7.2%)及資本設備(+5.7%)皆增長;AST 增長 9.6% 至 $1,138.5M,受定價與銷量帶動,儘管資本設備銷售大跌;生命科學增長 8.6% 至 $588.8M。

調整前分部經營收入為 $1,381.9M,但報告經營收入為 $1,101.8M,扣除已收購無形資產攤銷 $265.0M 及其他調整後。歸屬於股東的淨收入為 $782.3M,持續經營業務攤薄每股盈利為 $7.93。醫療保健分部利潤率由 25.0% 微跌至 24.6%,因關稅與通脹抵銷了銷量、定價及生產力帶來的改善。

收入按分部 — 2026財政年度

板塊收入佔比同比
醫療保健$4,208.6M70.9%+8.5%
應用滅菌技術(AST)$1,138.5M19.2%+9.6%
生命科學$588.8M9.9%+8.6%
收入總額$5,935.9M100%+8.7%
來源:STERIS 2026 財政年度 Form 10-K(年度截至 2026 年 3 月 31 日)分部收入及調整前分部經營收入。2025 財政年度比較數字:醫療保健 $3,878.7M、AST $1,038.6M、生命科學 $542.3M、總額 $5,459.5M。佔比與同比按披露分部收入計算。牙科列為已終止經營業務,全程剔除。

歷史沿革

年份里程碑
1985年微生物學家 Raymond Kralovic 於俄亥俄州門托創立 Innovative Medical Technologies
1987年更名為 STERIS Corporation;Bill Sanford 出任首任總裁兼行政總裁
1998年轉往紐約證券交易所上市,代碼 STE
2015年收購 Synergy Health,成為 STERIS plc
2021年收購 Cantel Medical,擴展內窺鏡與生命科學感染預防業務;Dan Carestio 出任總裁兼行政總裁
2025年出售牙科分部,其後列為已終止經營業務

競爭地位

  • 裝機服務模式——滅菌器與手術台一次銷售可帶來多年消耗品、維護及再處理收入;2026 財政年度醫療保健服務收入增長 11.8%。
  • AST 定價能力——醫療器械合約滅菌高度受監管且集中;AST 分部利潤率於 2026 財政年度達 46.1%。
  • 手術需求——人口老化及內窺鏡與篩查量上升,帶動無菌處理的穩定需求,不依賴任何單一藥物或器械週期。
  • 競爭——產品方面:3M、Baxter、Getinge、Ecolab、Olympus 與 Stryker;服務方面:Sterigenics 及器械製造商自行滅菌。

財務快照 — 2026財政年度

收入(持續經營業務)$5,935.9M(同比 +8.7%)
經營收入$1,101.8M(2025 財政年度為 $866.6M)
調整前經營收入$1,381.9M(2025 財政年度為 $1,267.5M)
歸屬於股東的淨收入$782.3M(2025 財政年度為 $614.6M)
持續經營業務攤薄每股盈利$7.93
自由現金流$982.9M(2025 財政年度為 $787.2M)
來源:STERIS 2026 財政年度 Form 10-K 合併報表及分部附註(年度截至 2026 年 3 月 31 日)。調整前經營收入為分部指標,剔除企業成本及已收購無形資產攤銷等項目(2026 財政年度為 $265.0M)。2025 財政年度數字已就已終止經營業務(牙科)重列。

主要風險

  • 關稅與通脹——10-K 將醫療保健利潤率下滑歸因於關稅成本與通脹跑贏定價及生產力改善。
  • 環氧乙烷風險——AST 滅菌使用環氧乙烷,整個合約滅菌行業皆面對排放監管與訴訟關注。
  • 資本設備波動——醫療保健資本收入季節性集中於財政年度第四季度,而 AST 資本設備銷售於 2026 財政年度大跌。
  • 按手術劃分的客戶集中——無單一客戶佔任何分部收入逾 10%,但需求最終跟隨醫院手術量與資本預算。

對標普500的重要性

STERIS 是標普500中感染預防的純粹代表,權重 0.03%:指數內醫院無菌處理與醫療器械滅菌的敞口,其業務隨手術量而非藥價或器械上市而增長。

其醫療保健服務增長與 AST 利潤率令其成為醫療保健板塊內低調的複合增長者,有別於主導板塊的藥廠與器械製造商。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 3 日抓取)· StockAnalysis(市值——2026 年 11 月 3 日抓取,單一來源)
財務STERIS 2026 財政年度 Form 10-K(SEC EDGAR,2026 年 5 月提交;財政年度截至 2026 年 3 月 31 日)
板塊分類GICS,據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

STERIS

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · STE
Data as of Nov 3, 2026 · Financials fiscal 2026 ended Mar 31, 2026 (10-K) · Market data Nov 2026
Previous · KeyCorp (KEY) — XLF Financials · S&P 500 Profile |KeyCorp公司介紹Next · T. Rowe Price Group, Inc. (TROW) — XLF Financials · S&P 500 Profile |普信集團公司介紹

Entered 2026-11-03 17:55 · updated 2026-11-15 00:03 · rev 5